Senescence Reprogramming Unleashes Tumor Immune Surveillance via Coordinated Gene Modulation

Area of Science:

• Oncology
• Immunotherapy
• Nanomedicine

Background:

• Cellular senescence, via the senescence-associated secretory phenotype (SASP), can recruit immune cells for tumor therapy.
• Therapeutic efficacy is often limited by immune tolerance and the immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To reprogram tumor-specific senescence by modulating P16INK4a and PD-L1 to enhance tumor immunogenicity and alleviate immunosuppression.
• To develop a targeted gene delivery nanoparticle for inducing tumor-specific senescence and improving immunotherapy outcomes.

Main Methods:

• Engineered a nanoparticle using urokinase plasminogen activator receptor (uPAR) for senescence-specific targeting.
• Incorporated a telomerase reverse transcriptase (TERT) promoter and NLS-MTAS peptide for efficient gene delivery.
• Evaluated in vivo anti-tumor response and therapeutic efficacy with αCTLA-4 immune checkpoint blockade in various tumor models.

Main Results:

• The nanoparticle successfully induced tumor-specific senescence via cell-cycle arrest.
• Demonstrated efficient chemotactic recruitment of cytotoxic immune cells.
• Achieved a robust anti-tumor response in vivo without systemic toxicity.
• Significantly enhanced the efficacy of αCTLA-4 immunotherapy across multiple tumor models.

Conclusions:

• Reprogramming tumor-specific senescence is a promising strategy to improve targeted gene delivery and immunotherapy.
• This approach offers a viable treatment for immunologically
• cold
• tumors.
• The developed nanoparticle system shows significant therapeutic potential for enhancing anti-tumor immunity.